Please ensure Javascript is enabled for purposes of website accessibility

5-Star Stocks Poised to Pop: China Medical

By Brian D. Pacampara, CFA - Updated Apr 5, 2017 at 8:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Market-trouncing returns could be written in this 5-star.

Based on the aggregated intelligence of 120,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health-care equipment maker China Medical Technologies (NYSE:CMED) has earned a coveted five-star ranking. Our data has shown that five-star stocks outperform the market by a significant margin; conversely, one-star stocks have woefully lagged the market average.

With that in mind, let's take a closer look at China Medical's business and see what CAPS investors are saying about the stock right now.

ChinaMedical facts

Headquarters (founded)

Beijing, China (1999)

Market Cap

$502.15 million


Medical Instruments & Supplies

TTM Revenue

$144.6 million


Founder/CEO Xiaodong Wu

CFO Takyung Tsang

TTM Return on Equity


Dividend Yield



Johnson & Johnson (NYSE:JNJ),

Abbott Labs (NYSE:ABT)

CAPS members bullish on CMED also bullish on

Suntech Power (NYSE:STP),

China Mobile (NYSE:CHL)

CAPS members bearish on CMED also bearish on

China Finance Online (NASDAQ:JRJC),

China Unicom (NYSE:CHU)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, fully 1,163 of the 1,191 members who have rated China Medical -- some 98% -- believe the stock will outperform the S&P 500 going forward. These Foolish bulls include lilly21 and ETFinnovators.

In October, lilly21 updated our community on some of the stock's developments: "Two new additions to their product line. They are awaiting FDA approval here and in Europe. They have approval in asia for their HIFU, FISH and skin diagnostic system. A no brainer long term."

In a pitch from last week, ETFinnovators chimed in on China Medical's recent purchase of a human papillomavirus (HPV) detection system:

China Medical is trading near its IPO levels of August 2005 despite excellent growth prospects and is a buy below 20 bucks with a dividend yield of 2.5% and market cap of $540M as uncertainty over a $345M acquisition has spooked some investors, sending the stock down sharply by over 50% in the past three months. The acquisition provides [China Medical] with a molecular diagnostics platform for HPV, including strains that cause cervical cancer – which is an estimated $700M market in China alone.

What do you think about China Medical, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 120,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Johnson & Johnson is a Motley Fool Income Investor pick. Suntech Power and China Finance Online are Rule Breakers selections. The Fool's disclosure policy always gets a perfect score.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$170.20 (-0.53%) $0.91
China Mobile Limited Stock Quote
China Mobile Limited
China Unicom (Hong Kong) Limited Stock Quote
China Unicom (Hong Kong) Limited
Abbott Laboratories Stock Quote
Abbott Laboratories
$109.00 (-0.23%) $0.25
China Finance Online Co. Limited Stock Quote
China Finance Online Co. Limited

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.